Pfizer Inc PFE

$29.39 -0.06 (-0.20%)

Valuation

Market cap
167,518,704,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.80
P/E (forward)
9.87
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
48,319,500
Avg volume
33,616,914
Day's range
$28.54 – $29.43
Shares out
5,699,854,000
Stochastic %K
29%
Beta
0.31
Analysts
Hold
Price target
$30.35

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

GTA_Terminal Nov 8, 9:06 AM
$PFE Options Flow Leans to Calls: A Smart-Money Check on the Stock. It's down about 4% from a week ago. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PFE&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PFE Read the full article for the full details: https://globaltradersacademy.com/articles/pfizer-pfe-options-flow-turns-bullish-a-smart-money-check-on-the-stock?utm_source=stocktwits&utm_medium=social
0 replies
thatsolardude365 Nov 8, 8:19 AM
$PFE ai drug discovery still has to survive a trial, a regulator, and a payer who asks what it costs. seems like the shortcut ends at the same three doors, and each door charges full price to pass
1 replies
Stocktradesmoon Nov 7, 11:01 PM
$ABCL $HIMS $REGN $PFE $MRNA $ABCL prints Monday. A biotech with a platform, not a product, is valued on the pipeline. The print is a cash check, not a revenue check.
0 replies
umiak1 Nov 7, 8:30 PM
$PFE Why Joe is Going "Longish" on Pfizer Your observation about his style is spot on: Joe Terranova isn't day trading this for a quick pop. He’s the Chief Market Strategist for Virtus Investment Partners and literal creator of the "Quality Momentum" ETF strategy (JOET). When he buys, he looks for structurally sound companies with long-term runway. Here is what aligns with his "long" thesis right now: • The Turnaround Play: After the post-COVID cliff, Pfizer spent a long time being punished by the market. Joe operates on identifying quality inflection points. • Crushing Earnings: Pfizer just reported a massive Q3 beat ($16.58 billion in sales vs. the expected $15.87 billion). Their adjusted earnings clocked in at 87 cents a share, entirely outpacing Wall Street's 72-cent expectation.
1 replies
taxplanr Nov 7, 6:06 PM
$PFE and $MRNA killed between 331,500 and 522,000 Americans in Florida with COVID injections https://www.instagram.com/reel/DfZ42KXRt0d/?obrf=MWhiZ2Rhb2lkc2x2Yg==
0 replies
GTA_Terminal Nov 7, 2:48 AM
Dark pool check on $PFE: what traded off the exchanges this session. Price barely moved (-0.2%), which is what you'd expect if somebody big is building or unwinding a position quietly. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PFE&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PFE Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-pfizer-pfe?utm_source=stocktwits&utm_medium=social
0 replies
PredictionFLO1 Nov 7, 1:04 AM
See the alerts behind today's flow — 14 days free: https://options.predictionflo.com/trial?via=st_trial_pm Today's board: $QQQ $MU $PFE
0 replies
BioTechHealthX Nov 6, 10:01 PM
$PFE Pfizer Inc. (NYSE: PFE) reported 55% operational growth in Padcev sales and raised its annual outlook. Can cancer medicines give its broader turnaround the momentum investors want? https://biotechhealthx.com/biotech-news/pfizer-pfe-gets-an-oncology-boost-as-padcev-sales-surge-55/
0 replies